RBC Capital lowered the firm’s price target on Viridian Therapeutics (VRDN) to $42 from $45 and keeps an Outperform rating on the shares. The company reported Q4 EPS while disclosing that Veli’ PDUFA is just a few months away on June 30th, and if approved, Viridian is gearing up for a commercial launch in TED in mid-2026, the analyst tells investors in a research note. RBC adds it continues to like the set-up for Viridian in 2026 as the company could transition to commercial stage and move closer to profitability.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics price target raised to $45 from $44 at Jefferies
- Viridian Therapeutics reports Q4 EPS ($1.08), consensus ($1.00)
- Strategic Buy on Viridian Therapeutics Ahead of Veligrotug PDUFA and Elegrobart Phase 3 REVEAL‑1 Readout
- Needham biotech analysts hold an analyst/industry conference call
- Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI